Theresa A. Proia

AstraZeneca (United States) — United States

Medicine · Health Sciences

14h-index1.7kcitations157works7.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(74), Cytokine Signaling Pathways and Interactions(44), Cancer-related Molecular Pathways(26), Immune cells in cancer(26), Lung Cancer Treatments and Mutations(24)

Publications157 total

Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in patients with endometrial cancer: A first-in-human phase I/IIa study
Gynecologic Oncology·2025· 1 cited
Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor
Journal of Medicinal Chemistry·2025· 15 cited
Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors
RSC Medicinal Chemistry·2025Open Access
606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
Annals of Oncology·2024· 14 citedOpen Access
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer
BMJ Oncology·2024· 8 citedOpen Access
Quantitative evaluation of <scp>trastuzumab deruxtecan</scp> pharmacokinetics and pharmacodynamics in mouse models of varying degrees of <scp>HER2</scp> expression
CPT Pharmacometrics & Systems Pharmacology·2024· 12 citedOpen Access
Abstract 1366: Dual immune checkpoint inhibition enhances the anti-tumor activity of trastuzumab deruxtecan in preclinical models
Cancer Research·2024· 1 cited
Abstract 3453: First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion
Cancer Research·2023· 3 cited
Abstract 3999: Combination of T-DXd with the irreversible pan-HER TKI afatinib drives combination benefit in HER2-low gastric and lung tumors
Cancer Research·2023
Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figures from Epithelial-to-Mesenchymal Transition Activates PERK–eIF2α and Sensitizes Cells to Endoplasmic Reticulum Stress
2023Open Access
Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S12 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Data from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Table S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figures S1-3 and Table S1 from 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity
2023Open Access
Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S9 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional &lt;i&gt;STK11&lt;/i&gt; Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Maryann San Martin(13), Lisa Drew(11), Matthew Griffin(11), Wenlin Shao(10), Nabendu Pore(10), Nathan Standifer(10), Maria Jure‐Kunkel(10), Yashaswi Shrestha(10), Rebecca Halpin(10), Raymond Rothstein(10), Kathy Mulgrew(10), Philip Martin(10), John Meekin(10), Ina Bisha(10), Ricardo J. Miragaia(10), Ronald Herbst(10), Ashok Gupta(10), Shaad E. Abdullah(10), Rajiv Raja(10), Melanie M. Frigault(10)